Both researchers and practitioners will find this authoritative volume an excellent source of information on novel immune targeted therapeutics.

Informationen zum Autor Dr. Larson and Dr. Watson have worked together researching the role of immune and cytokine dysfunction in heart disease for 8 years. They have been and currently are funded to do such research by grants from the U.S. National Institute of Heart, Lung and Blood, the American Heart Foundation, companies and private foundations. Dr. Watson has edited 62 scientific books, including several dealing with heart disease and conditions such as aging and AIDS that promote immune dysfunction as well as heart disease. Dr. Larson directs the Center's organ perfusion program as well as its Master degree in pharmacology and toxicology for perfusion students. ____ Ronald Ross Watson Ph.D. Professor Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health and the Sarver Heart Center in the School of Medicine, University of Arizona, P. O. Box 245155, 1501 N. Campbell Avenue, Tucson, AZ 85749. (520) 626 2850, Fax (520) 626 6093 rwatson@u.arizona.edu ____ Douglas F. Larson Ph.D. Professor Surgery and the Sarver Heart Center in the School of Medicine, University of Arizona, P. O. Box 245066, 1501 N. Campbell Avenue, Tucson, AZ 85749. (520) 626 6494 dflarson@email.arizona.edu Klappentext Current heart failure therapeutics affects symptoms without appreciably reducing the mortality rate of 50% in five years -- suggesting a failure in treating the underlying mechanism. This book proposes a new mechanism for heart failure; immune mediated cardiac remodelling for cardiac dysfunction.The outstanding editor team of two internationally recognized immunologists -- Ronald Watson, who has studied heart disease in immune dysfunction for a decade and has a patent for an immunotherapy of heart disease by immune regulation, and Douglas Larson, whose experience in cardiac transplantation immunology has provided the foundation for research into novel therapeutics for heart failure and hypertension - makes Immune Dysfunction and Immunotherapy in Heart Disease the definitive reference to the state of the science in this area.The four parts of the book address: Immune Dysfunction Leading to Heart Disease: Induction by Physiological Changes Immune Dysfunction Promoting CVD: Induction by Transplantation Drugs Immune Dysfunction Leading to Heart Dysfunction: Induction or Prevention by Cardiotherapeutic Drugs Immune Dysfunction Leading to Heart Disease: Induction by PathogensBoth researchers and practitioners will find this authoritative volume an excellent source of information on novel immune targeted therapeutics. Zusammenfassung Current heart failure therapeutics affects symptoms without appreciably reducing the mortality rate of 50% in five years -- suggesting a failure in treating the underlying mechanism. This book proposes a new mechanism for heart failure; immune mediated cardiac remodelling for cardiac dysfunction. Inhaltsverzeichnis Contributors. Preface. About the Editors. Part I Immune dysfunction leading to. heart disease: induction by. physiological changes . 1 Immunosuppression by ultraviolet light-B. radiation: amediator of cardiac remodeling. Sherma Zibadi (The University of Arizona), Douglas F. Larson (Sarver Heart Center In the School of Medicine) & Ronald. Ross Watson (Sarver Heart Center in the School of Medicine). 2 Immune mechanisms in pediatric. cardiovascular disease. Wendy A. Luce (Childrens Research Institute), Mandar S. Joshi (Center for Cardiovascular Medicine, Columbus), Timothy M. Hoffman, Timothy (Columbus Children's Heart Center), F. Feltes (Childrens Research Institute) & John Anthony. ...

Klappentext

Current heart failure therapeutics affects symptoms without appreciably reducing the mortality rate of 50% in five years -- suggesting a failure in treating the underlying mechanism. This book proposes a new mechanism for heart failure; immune mediated cardiac remodelling for cardiac dysfunction. The outstanding editor team of two internationally recognized immunologists -- Ronald Watson, who has studied heart disease in immune dysfunction for a decade and has a patent for an immunotherapy of heart disease by immune regulation, and Douglas Larson, whose experience in cardiac transplantation immunology has provided the foundation for research into novel therapeutics for heart failure and hypertension - makes Immune Dysfunction and Immunotherapy in Heart Disease the definitive reference to the state of the science in this area. The four parts of the book address: Immune Dysfunction Leading to Heart Disease: Induction by Physiological Changes Immune Dysfunction Promoting CVD: Induction by Transplantation Drugs Immune Dysfunction Leading to Heart Dysfunction: Induction or Prevention by Cardiotherapeutic Drugs Immune Dysfunction Leading to Heart Disease: Induction by Pathogens Both researchers and practitioners will find this authoritative volume an excellent source of information on novel immune targeted therapeutics.

Inhalt

Contributors. Preface.

About the Editors.

Part I Immune dysfunction leading to.

heart disease: induction by.

physiological changes.

1 Immunosuppression by ultraviolet light-B.

radiation: amediator of cardiac remodeling.

Sherma Zibadi (The University of Arizona), Douglas F. Larson (Sarver Heart Center In the School of Medicine) & Ronald.

Ross Watson (Sarver Heart Center in the School of Medicine).

2 Immune mechanisms in pediatric.

cardiovascular disease.

Wendy A. Luce (Childrens Research Institute), Mandar S. Joshi (Center for Cardiovascular Medicine, Columbus), Timothy M.

Hoffman, Timothy (Columbus Children's Heart Center), F. Feltes (Childrens Research Institute) & John Anthony.

Bauer (Wexner Child Hospital, Ohio State University).

3 Heart failure-role of autoimmunity.

Urs Eriksson (Universitatsspital).

4 Immune basis of hypertension in humans.

Katherine Horak (Sarver Heart Center, The University of Arizona) & Douglas F. Larson (Sarver Heart Center In the School of Medicine).

5 Immune dysregulation: potential mediator of.

metabolic syndrome-induced cardiac.

remodeling.

Sherma Zibadi (The University of Arizona), Douglas F. Larson (Sarver Heart Center In the School of Medicine) & Ronald.

Ross Watson (Sarver Heart Center in the School of Medicine).

6 T helper 2 cell cytokines in remodeling of.

aortic wall.

W. L. Chan (William Harvey Research Institute).

7 Effects of TNF- on cardiac function.

Bo Yang (University of Arizona) & Douglas F. Larson (Sarver Heart Center In the School of Medicine).

8 Immunosuppression in promotion of cardiac.

allograft vasculopathy.

Farzad Moien-Afshari (University of British Columbia), Jonathan Choy (Department of Pharmacology and Therapeutics), Bruce.

M. McManus (Department of Pharmacology and Therapeutics) & Ismail Laher (University of British Columbia).

9 Immunotherapy for left.

ventricular dysfunction after.

heart transplantation.

Charles E. Canter (Washington University School of Medicine).

Part II Immune dysfunction promoting.

CVD: induction by transplantation.

drugs.

10 Immunomodulating therapy in chronic heart.

failure.

Lars Gullestad (Department of Cardiology, University of Oslo, N-0027 Oslo, Norway).

, Jan Kristian Dam°as (Research Institute for Internal Medicine),.

Arne Yndestad (Research Institute for Internal Medicine, University of Oslo) & P°al Aukrust (Rikshospitalet).

11 Statins in atherosclerosis: role of immune.

regulation.

Claire Arnaud & Fran cois Mach (Foundation for Medical Research).

12 ACE inhibitors as immunomodulators:.

treatment of cardiovascular disease.

Christina Grothusen (Dept. of Cardiology and Angiology) & Bernhard …